GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.

The diabetes drugs, which usually cost about $525, are listed on TrumpRx starting around $55. The COPD inhaler drops from ...

Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...

SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 receptor ...

Inhaled chronic obstructive pulmonary disease (COPD) medications prescribed before surgery in patients with early-stage non–small cell lung cancer (NSCLC) were associated with both short- and ...

HealthDay News — In older adults, depression is associated with decreased adherence to maintenance medication regimens for chronic obstructive pulmonary disease (COPD), according to a study published ...

Use of CT is proven to save lives in patients eligible for lung cancer screening, which includes most patients with COPD, said Barr, professor of medicine and epidemiology at Columbia University ...

An acute pulmonary embolism occurs when a blood clot blocks one or more vessels in the lung. In patients at moderate or high risk, the blockage can impair the heart's ability to pump blood through the ...

India, March 29 -- Progressive pulmonary fibrosis (PPF), a serious form of interstitial lung disease, remains one of the most ...